Replies to post #35941 on Relief Therapeutics Holding AG (RLFTF)

[Inelgr]

Correct, if your looking at this from a stock price only perspective.

Incorrect, if your looking at this from a medical/scientific perspective.

If people were looking to "go to the moon" or "pay off my student loans" or "buy a lambo" overnight with this stock, they are...and will be, very disappointed because the life/pharmaceutical science and medical professionals behind this drug are NOT that type of pump n dump scam artists.

Dr. Javitt is a serious kinda medical guy. He isn't looking at this in terms of stock price. His primary, and even secondary concern isn't PR for stock price performance. You will be constantly disappointed if you think/expect otherwise.
If he's ever going to be concerned with "Public Relations," it will be to let the medical world, and by extension...the rest of the population know, that Zyesami is an important therapeutic that can help save lives. And that's just going to have to take some time....even with Covid.

As for the stock price...this is a long term play.

For those that are interested in the science, there are many articles written and interviews given about it. The latest is very informative....and encouraging.
Discussion with Dr. Javitt, CEO NeuroRx

[Inelgr]

b.t.w. Dr. Javitt explained exactly why the "28 day" Primary Outcome was put into the study. It's a relic from the 1990's and basically "procedural."

The interview explains all of that and what their actual Primary Outcome is and how they are meeting it and what the FDA will be looking at.

Those concerned about the 28 day marker shouldn't be. It's a giant nothing-burger in the larger picture.